Dr Valentina Gburcik is an analyst at GlobalData covering cardiovascular and metabolic disorders.
Follow Valentina Gburcik: Website |
May 30, 2013 7:12 am by Valentina Gburcik | 1 Comments
Takeda announced positive late-stage results for its new type 2 diabetes drug, fasiglifam (TAK-875), the first GPR40 agonist to reach late-stage development. Fasiglifam has the potential to be a compelling…
GOT NEWS? SEND US A TIP
Get our daily newsletter or follow us.
By Meghana Keshavan | 4:13 pm, July 23 | 0 Comments
By Veronica Combs | 2:06 pm, July 23 | 0 Comments
By Stephanie Baum | 12:36 pm, July 23 | 0 Comments
By Mark Sullivan | 9:21 am, July 23 | 0 Comments
By Stephanie Baum | 7:00 am, July 23 | 0 Comments
By Dan Verel | 5:22 am, July 23 | 0 Comments